Immucell (ICCC) Total Liabilities (2010 - 2026)
Immucell's (ICCC) quarterly Total Liabilities came in at $15.5 million in Q4 2025, down 11.97% YoY from $17.6 million in Q4 2024, and down 2.84% on a QoQ basis from $15.9 million in Q3 2025.
Immucell (ICCC) Total Liabilities (2010 - 2026) Analysis & Trends
Immucell (ICCC) has 16 years of Total Liabilities data on file, last reported at $15.5 million in Q4 2025.
- Quarterly Total Liabilities fell 11.97% year-over-year to $15.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $15.5 million (down 11.97% YoY) and the FY2025 annual result came in at $15.5 million, down 11.97% from the prior year.
- Total Liabilities declined to $15.5 million in Q4 2025, from $15.9 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $18.8 million in Q4 2023 to a low of $11.5 million in Q2 2021.
- A 5-year average of $15.5 million and a median of $15.7 million in 2025 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2023 — Total Liabilities climbed 29.93% — and 2025, when it dropped 11.97%.
- Tracing ICCC's Total Liabilities over 5 years: stood at $11.9 million in 2021, then gained by 21.8% to $14.5 million in 2022, then grew by 29.93% to $18.8 million in 2023, then slipped by 6.55% to $17.6 million in 2024, then slipped by 11.97% to $15.5 million in 2025.
- The last three Total Liabilities figures came in at $15.5 million (Q4 2025), $15.9 million (Q3 2025), and $16.9 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.29 Bn | 131.44 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 86.31 Bn | 78.32 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 65.22 Bn | 60.03 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.92 Bn | 53.78 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 42.07 Bn | 36.97 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.70 Bn | 28.39 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 27.99 Bn | 9.60 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.28 Bn | 26.45 Bn | - | 10.03 Bn |
| 10 | Immucell | 93.37 Mn | 84.51 Mn | 2.44 Mn | 15.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 15.26 Mn |
| Dec 31, 2025 | 15.48 Mn |
| Sep 30, 2025 | 15.93 Mn |
| Jun 30, 2025 | 16.85 Mn |
| Mar 31, 2025 | 16.63 Mn |
| Dec 31, 2024 | 17.58 Mn |
| Sep 30, 2024 | 18.04 Mn |
| Jun 30, 2024 | 18.40 Mn |
| Mar 31, 2024 | 18.41 Mn |
| Dec 31, 2023 | 18.82 Mn |
| Sep 30, 2023 | 18.53 Mn |
| Jun 30, 2023 | 17.15 Mn |
| Mar 31, 2023 | 14.96 Mn |
| Dec 31, 2022 | 14.48 Mn |
| Sep 30, 2022 | 14.42 Mn |
| Jun 30, 2022 | 13.43 Mn |
| Mar 31, 2022 | 13.55 Mn |
| Dec 31, 2021 | 11.89 Mn |
| Sep 30, 2021 | 11.77 Mn |
| Jun 30, 2021 | 11.46 Mn |